Paolo Cozzolino

Dr. Paolo Cozzolino

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
PVPaola Della Valle
Paola Della Valle
MFMarco Fabbri
Marco Fabbri
FMFabiana Madotto
Fabiana Madotto
Pietro FerraraPietro Ferrara
Pietro Ferrara
PCPaolo Cozzolino
Paolo Cozzolino
TGThe MUSTANG–OCCUPATION–COVID-19 Study Group
The MUSTANG–OCCUPATION–COVID-19 Study Group
Sero-epidemiological surveys are valuable attempts to estimate the circulation of SARS-CoV-2 in general or selected populations. Within this context, a prospective observational study was conducted to estimate the prevalence and persistence of SARS-CoV-2 antibodies in different categories of workers and factors associated with positivity, through the detection of virus-specific immunoglobulin G and M (IgG/IgM) in serum samples. Enrollees were divided in low exposure and medium-high groups on the basis of their work activity. Antibody responders were re-contacted after 3 months for the follow-up. Of 2255 sampled workers, 4.8% tested positive for SARS-CoV-2 IgG/IgM antibodies, with 81.7% to IgG only. Workers who continued to go to their place of work, were healthcare workers, or experienced at least one COVID-19-related symptom were more likely to test positive for SARS-CoV-2 antibodies. SARS-CoV-2 antibodies prevalence was significantly higher in the medium-high risk vs. low-risk group (7.2% vs. 3.0%, p < 0.0001). At 3-month follow-up, 81.3% of subjects still had antibody response. This study provided important information of SARS-CoV-2 infection prevalence among workers in northern Italy, where the impact of COVID-19 was particularly intense. The presented surveillance data give a contribution to refine current estimates of the disease burden expected from the SARS-CoV-2.

1 November 2013 in Value in Health
Verified
Journal Article
Closed access
PCPaolo Angelo Cortesi
Paolo Angelo Cortesi
LSL. Scalone
L. Scalone
RCR. Ciampichini
R. Ciampichini
PCPaolo Cozzolino
Paolo Cozzolino
GCG. Cesana
G. Cesana
MSM. Strazzabosco
M. Strazzabosco

24 December 2023 in Medicina
Verified
Journal Article
Open access
PDF file
IAIppazio Cosimo Antonazzo
Ippazio Cosimo Antonazzo
PCPaolo Angelo Cortesi
Paolo Angelo Cortesi
EZEzio Zanon
Ezio Zanon
SPSamantha Pasca
Samantha Pasca
MMMassimo Morfini
Massimo Morfini
LMLorenzo Mantovani
Lorenzo Mantovani
Background and Objectives: This study aimed to assess the effectiveness and costs associated with pharmacokinetics-driven (PK) prophylaxis based on the myPKFiT® device in patients affected by hemophilia A (HA) in Italy. Materials and Methods: An observational retrospective study was conducted in three Italian hemophilia centers. All patients with moderate or severe HA, aged ≥ 18 years, capable of having PK estimated using the myPKFiT device, and who had had a clinical visit between 1 November 2019 and 31 March 2022 were included. Differences in clinical, treatment, health resources, and cost data were assessed comparing post-PK prophylaxis with pre-PK. The incremental cost-effectiveness ratio (ICER) was estimated as cost (EUR) per bleed avoided. Results: The study enrolled 13 patients with HA. The mean annual bleeding rate decreased by −1.45 (−63.80%, p = 0.0055) after the use of myPKFiT®. Overall, the consumption of FVIII IU increased by 1.73% during follow-up compared to the period prior the use of the myPKFiT. Prophylaxis based on the myPKFiT resulted in an ICER of EUR 5099.89 per bleed avoided. Conclusions: The results of our study support the idea that the use of PK data in clinical practice can be associated with an improvement in the management of patients, as well as clinical outcomes, with a reasonable increase in costs.

21 February 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
LMLorenzo Mantovani
Lorenzo Mantovani
PCPaolo Cozzolino
Paolo Cozzolino
Pietro FerraraPietro Ferrara
Pietro Ferrara
SVSaverio Virdone
Saverio Virdone
ACA. John Camm
A. John Camm
OIon behalf of the GARFIELD-AF Investigators
on behalf of the GARFIELD-AF Investigators
The management of atrial fibrillation (AF), the most common sustained arrhythmia, impacts healthcare resource utilization (HCRU). This study aims to estimate global resource use in AF patients, using the GARFIELD-AF registry. A prospective cohort study was conducted to characterize HCRU in AF patients enrolled in sequential cohorts from 2012 to 2016 in 35 countries. Components of HCRU studied were hospital admissions, outpatient care visits, and diagnostic and interventional procedures occurring during follow-up. AF-related HCRU was reported as the percentage of patients demonstrating at least one event and was quantified as rate-per-patient-per-year (PPPY) over time. A total of 49,574 patients was analyzed, having an overall median follow-up of 719 days. Almost all patients (99.5%) had at least one outpatient care visit, while hospital admissions were the second most frequent medical contact, with similar proportions in North America (37.5%) and Europe (37.2%), and slightly higher in the other GARFIELD-AF countries (42.0%; namely Australia, Egypt, and South Africa). Asia and Latin America showed lower percentages of hospitalizations, outpatient care visits, and diagnostic and interventional procedures. Analyses of GARFIELD-AF highlighted the vast AF-related HCRU, underlying significant geographical differences in the type, quantity, and frequency of AF-related HCRU. These differences were likely attributable to health service availability and differing models of care.

1 November 2014 in Value in Health
Verified
Journal Article
Closed access
PCPaolo Angelo Cortesi
Paolo Angelo Cortesi
MRM. Rota
M. Rota
LSL. Scalone
L. Scalone
PCPaolo Cozzolino
Paolo Cozzolino
GCG. Cesana
G. Cesana
MSM. Strazzabosco
M. Strazzabosco

1 November 2015 in Value in Health
Verified
Journal Article
Closed access
PCPaolo Cozzolino
Paolo Cozzolino
PCPaolo Angelo Cortesi
Paolo Angelo Cortesi
RAR Assietti
R Assietti
FCF Cuzzocrea
F Cuzzocrea
DPD Prestamburgo
D Prestamburgo
GCG Cesana
G Cesana